Skip to main content

MRSA Colonization

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

B. Braun
B. BraunGermany - Melsungen
1 program
1
MupirocinPhase 41 trial
Active Trials
NCT01400308Terminated99Est. Dec 2011
Biocorp
BiocorpFrance - Issoire
1 program
1
Bio-K+ CL1285Phase 21 trial
Active Trials
NCT00941356Withdrawn0Est. Jul 2016
Plus Therapeutics
1 program
Bio-K+ CL1285PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
B. BraunMupirocin
BiocorpBio-K+ CL1285

Clinical Trials (2)

Total enrollment: 99 patients across 2 trials

Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)

Start: Feb 2010Est. completion: Dec 201199 patients
Phase 4Terminated
NCT00941356BiocorpBio-K+ CL1285

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Start: Jan 2010Est. completion: Jul 20160
Phase 2Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.